secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2024-08-28T23:59:59+00:00
Accession:  0001711279-24-000045
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jeune Aesthetics reports positive Phase 1 interim results for KB301 in wrinkles; plans Phase 2 for décolleté
--------------------------------------------------------------------------------

- 94% of décolleté subjects had ≥1-point improvement on GAIS at two months; 89% reported improved wrinkle satisfaction.
- 75% of lateral canthal subjects had ≥1-point improvement on GAIS at two months; 67% reported improved satisfaction.
- No drug-related serious adverse events; adverse events were mild-to-moderate and transient.
- Phase 2 study for dynamic wrinkles of the décolleté expected to start next year; FDA meeting planned.
- Improvements also seen in crepiness, hydration, and radiance in both cohorts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127924000045/0001711279-24-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127924000045/krys-20240828.htm
  HTML page:      https://secwatch.observer/filing/0001711279-24-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer